Skip to main content
Premium Trial:

Request an Annual Quote

Alamar Biosciences NULISAseq CNS Disease Panel 120 and NULISAqpcr pTau-217 Assay

Alamar Biosciences said this week it has launched its NULISAseq CNS Disease Panel 120 for analysis of 120 proteins implicated in major neurological disorders and its NULISAqpcr pTau-217 Assay for focused measurement of the Alzheimer's biomarker phosphorylated-tau 217. Both assays run on the company's Argo HT system.